New nanotherapy clears amyloid-β reversing Alzheimer’s in mice - Drug Target Review
Discover groundbreaking research on Alzheimer's that reverts the disease in mice using innovative nanotechnology strategies.| Drug Target Review
Discover groundbreaking research on Alzheimer's that reverts the disease in mice using innovative nanotechnology strategies.| Drug Target Review
To quantify the impacts on biomedical research and innovation that NIH funding cuts might have, researchers analyzed small-molecule drug patents to determine how many NIH funded projects were involved in the discovery and development of those drugs. The post NIH Funding Cuts’ Impact on Drug Discovery and Development appeared first on GEN - Genetic Engineering and Biotechnology News.| GEN – Genetic Engineering and Biotechnology News
It turns out that AI really is doing the work. At least a growing chunk of it. Artificial intelligence is spreading through the global workforce like wildfire, dwarfing the adoption pace of the internet, with a new Anthropic report citing Gallup research that 40% of U.S. employees now use AI at work. While the field… The post As the pharma industry grapples with a talent shortfall, AI makes inroads in drug-safety workflows appeared first on Drug Discovery and Development.| Drug Discovery and Development
Eli Lilly launched “TuneLab,” an AI/ML platform that gives selected biotechs access to drug-discovery models trained on years of Lilly research data. Initial public partners include Circle Pharma and insitro. Lilly says the first release reflects more than $1B worth of internal data investment. Lilly says biotechs run its models locally on their own infrastructure… The post Lilly launches TuneLab, sharing AI drug-discovery models with biotechs appeared first on Drug Discovery and Develo...| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
By Ram Aiyar, CEO of Korro Bio, as part of the From The Trenches feature of LifeSciVC Let me tell you a secret that most biotech executives won’t admit at cocktail parties: we’re all making it up as we go The post Speed Wins: The Focused-Team Formula for Platform Biotechs appeared first on LifeSciVC.| LifeSciVC
Healthcare is one of the largest sources of “big data,” accounting for upwards of 30% of all data produced globally.1 Early on, the potential benefits of this data for healthcare outcomes were immediately evident. As that promise has begun to materialize, with the advent of AI and machine learning, real signals of improvement in therapeutic… The post Early-phase study design considerations for long-term follow-up in vaccine clinical trials appeared first on Drug Discovery and Development.| Drug Discovery and Development
Antibodies from a person who had previously been infected with mpox provides full protection from severe illness and death in mice.| GEN - Genetic Engineering and Biotechnology News
The one-drug-many-indications model has steadily grown in popularity since the early 2000s. But Irvine, California–headquartered Tarsus Pharmaceuticals is aiming to bring the model to XDEMVY (lotilaner), an antiparasitic drug that first won FDA-approval in dogs. After licensing lotilaner from Elanco, Tarsus won FDA approval for the drug, under the trade name XDEMVY, for the treatment… The post Q2 net sales reach $100M for Tarsus’ XDEMVY, a potential treatment for Lyme and malaria rooted...| Drug Discovery and Development
Bispecific antibodies are a rapidly advancing class of therapeutics, offering a new level of precision in treating diseases like cancer.| Drug Discovery and Development
The movement of epithelial cells during wound healing is mediated by the endoplasmic reticulum, which senses the curvature of wound gaps.| GEN - Genetic Engineering and Biotechnology News
VantAI's AI platform will accelerate programmable protein interaction therapies across Halda's cancer and immunology indications.| GEN - Genetic Engineering and Biotechnology News
Researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.| GEN - Genetic Engineering and Biotechnology News
As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward...| HotSpot Therapeutics
Learn how Deep Science Ventures’ zero-data approach tackles biotech’s early funding challenges to speed innovation and reduce risk.| Labiotech.eu
NATO Innovation Fund backs Portal Biotech in its first biotech move. What does this signal for strategic investment in healthcare innovation?| Labiotech.eu
Liu’s research focuses on the discovery of small molecules for human proteins, as well as the functional characterization of these proteins in physiological and disease contexts.| wertheim.scripps.ufl.edu
Half of glioblastoma patients have a subtype that doesn’t respond to any approved cancer drugs. A new experimental treatment from The Wertheim UF Scripps Institute shows promise in mouse studies. Clinical trials are coming soon.| The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Tec...
Alex Tropsha is part of a multi-million dollar, federally funded project using machine learning to identify new uses for existing drugs.| UNC Research Stories
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
The once pioneering DNA test company 23andMe is now a penny stock that has filed for bankruptcy. Its CEO Anne Wojcicki is also stepping down.| Drug Discovery and Development
His paper was called “the miracle result.” But it never turned into an Alzheimer’s treatment. Now, four former Genentech senior scientists and executives allege that an internal review in 2011 discovered the paper had been based on fabricated research — and that Marc Tessier-Lavigne kept the results of the review from becoming public. He denies the allegations.| The Stanford Daily
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which The post A New Wave of Therapeutic Innovation Through Targeting Transcription Factors appeared first on LifeSciVC.| LifeSciVC
"Discovering new medicines is challenging work that requires the expertise of many. There are real synergies for our scientists and students as we build collaboration among departments," said Matthew Disney, Ph.D., chair of The Wertheim UF Scripps chemistry department.| wertheim.scripps.ufl.edu
Children born with a damaged gene needed for healthy brain development, SYNGAP1, experience seizures, sensory processing disorders, difficulty speaking, intellectual disability, and autism-like behaviors. It’s a condition without any treatments, one that’s hard both on parents and children, said Gavin Rumbaugh, Ph.D., a neuroscientist at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation &…| wertheim.scripps.ufl.edu
In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one...| HotSpot Therapeutics
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development
PubMiner AI aims to help researchers in the biomedical domain overcome the challenges in automatic knowledge extraction from large volumes of scientific publications. The post Advancing Automatic Knowledge Extraction with PubMiner AI appeared first on Ontotext.| Ontotext
Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health.| Labiotech.eu
Dr. Hendrik Luesch’s new joint appointment will expand UF’s natural products research to one of the world’s prime areas for marine biodiversity.| pharmacy.ufl.edu
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.| Labiotech.eu
A new computational screening system using AI could lead to more efficient, cost-effective and expansive search for novel therapeutic drugs.| Promega Connections
At HotSpot, we’re harnessing insights from nature by pinpointing specialized protein on/off switches, or pockets, called “natural hotspots.” To date,...| HotSpot Therapeutics
Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used...| HotSpot Therapeutics
At HotSpot, we are committed to building something we believe is truly distinctive, setting ourselves apart from our peers in...| HotSpot Therapeutics
Every company has a culture, either by design or default. From our inception in 2016, we wanted to create a...| HotSpot Therapeutics
The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...| HotSpot Therapeutics
